Clinical trials
Pediatric Oncology clinical trials
Below are recruiting pediatric oncology clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06485947RecruitingPhase 1
Study testing dinutuximab beta with chemotherapy for neuroblastoma
This trial combines the immunotherapy drug dinutuximab beta with two different chemotherapy regimens to see if it works better for children with high-risk neuroblastoma that has spread. It may be an option for newly diagnosed patients who have not had cancer treatment before.
Utrecht, UtrechtAges 1.5 years–18 years - NCT05658640RecruitingPhase 1/Phase 2
Testing trametinib and steroid plus chemo for relapsed blood cancers
This early-phase trial tests whether adding trametinib and dexamethasone to standard chemotherapy can improve outcomes for children whose blood cancer has come back or did not respond. Because it is a Phase 1/2 study, the main goal is to see safety and learn the best way to treat your specific cancer type.
ViennaAges 1–21 - NCT05751044RecruitingPhase 1/Phase 2
Study of four medicines for children with difficult blood cancers
This Phase 1/2 trial tests a combination of medicines (dasatinib, venetoclax, dexamethasone, cyclophosphamide, and cytarabine) in children and teens whose blood cancer has come back or did not respond to treatment. It aims to see whether this approach can control the cancer while checking what doses are safe.
ViennaAges 1–21 - NCT05745714RecruitingPhase 1/Phase 2
Targeted triple-combination treatment for children with relapsed blood cancers
This Phase 1/2 study tests a multi-drug combination (ruxolitinib, venetoclax, dexamethasone, plus chemotherapy) for children whose blood cancer has come back or did not respond. It aims to reduce the cancer by targeting specific genetic changes and may offer a new option when standard treatments have not worked.
ViennaAges 1–21 - NCT05867186Recruiting
Get fit during childhood cancer treatment and aftercare
This trial tests a “fit to fight” program to help children and teens stay active during and after cancer treatment. It aims to support physical and possibly emotional well-being while treatment is happening, based on whether your care team thinks it’s safe and helpful for you.
Mainz, Rhineland-PalatinateAges 3–21 - NCT05754840RecruitingPhase 1/Phase 2
Cannabinoid treatment for children with hard-to-treat cancers
This early-phase study tests whether a cannabinoid medicine (including nabilone/cannabis-based treatment) can be given safely to children and teens with relapsed or refractory cancer. It may help with treatment options for children whose cancer has come back or did not respond to standard therapy.
Vancouver, British ColumbiaAges 4–18 - NCT05407480Recruiting
Treatment guidance study for children with Hodgkin lymphoma
This study is for children with “classical” Hodgkin lymphoma to help guide the best treatment plan. It may help your care team choose therapy based on what has worked for similar children.
Paris, FranceAges birth–18 years - NCT05327894RecruitingPhase 3
Infants with a specific leukemia genetic change
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Buenos AiresAges 1 day–1 year - NCT05270096Recruiting
Matches children and young people to leukemia treatment plans
This trial is set up to review tumor lab test results to help doctors choose the most appropriate next treatment for people with leukemia that has returned or did not respond. It mainly matters for younger patients who are not already on a standard treatment path.
GhentAges birth–25 years - NCT05306509Recruiting
Early palliative care talks for kids with cancer
This trial tests whether nurse-led conversations about comfort and support (palliative care) early in a child’s cancer journey can help families and the child cope better. It is focused on newly diagnosed or relapsed pediatric cancer patients in Chinese-speaking settings.
Shanghai, MinhangAges Up to 18 years - NCT04794296Recruiting
Care plan for children newly diagnosed with acute lymphoblastic leukemia
This trial uses a standard treatment plan for children who have just been diagnosed with acute lymphoblastic leukemia (ALL). It aims to guide the best initial treatment for certain cell types of ALL and help improve outcomes while avoiding specific higher-risk subtypes.
AbidjanAges Up to 18 years - NCT04425421Recruiting
Treatment plan for children with Burkitt lymphoma
This trial uses a recommended treatment approach for children who have Burkitt lymphoma, a specific type of blood cancer. It may help by guiding care when the full standard treatment schedule can’t be followed for every child.
OuagadougouAges Up to 18 years - NCT04423484Recruiting
Treatment plan study for newly diagnosed one kidney tumor
This trial looks at what treatment recommendations work best for children with a nephroblastoma (Wilms tumor) that is in only one kidney and has not been treated yet. It may help doctors choose the best next steps for care while the child’s overall health supports treatment.
OuagadougouAges 6 months–18 years - NCT04425434Recruiting
Treatment plan study for children with retinoblastoma
This trial looks at care recommendations for children with retinoblastoma (a childhood eye cancer). It may help standardize the best treatment approach for different patterns of tumor spread.
OuagadougouAges Up to 18 years - NCT02530658Recruiting
Sequencing children’s tumor and normal tissue samples
This study collects children’s normal and tumor tissue (or blood-related normal samples) and reads their DNA/RNA to look at genetic information. It may help researchers understand cancer-related changes and improve future testing, even when the goal isn’t to treat you directly.
Memphis, TennesseeAges Any age - NCT05029531RecruitingPhase 3
Immuno-chemotherapy for infants with B-lineage ALL
This trial tests a combination of medicines (immunotherapy plus chemotherapy) in babies diagnosed with a type of leukemia called B-lineage acute lymphoblastic leukemia (ALL). It aims to improve how well treatment works and is delivered safely in very young children.
Moscow, Samory-Mashela,1Ages 1 day–12 months - NCT07375563RecruitingPhase 3
Chemoimmunotherapy with NK cells for high-risk neuroblastoma
This trial tests a combination of chemotherapy, immunotherapy, and natural killer (NK) cell therapy for children with high-risk neuroblastoma or ganglioneuroblastoma that has not responded to initial treatment or has come back after treatment. The goal is to see if this approach can help destroy cancer cells more effectively.
MoscowAges 1.5 years–18 years - NCT05518383RecruitingPhase 4
Pediatric B-cell lymphoma treatment study using established care
This trial studies treatment for children and teens with certain B-cell non-Hodgkin lymphomas using a specific treatment protocol. It may help doctors confirm how well the regimen works in young patients and improve care over time.
Moscow, RFAges 1 day–18 years - NCT05549167RecruitingPhase 3
Sirolimus for children with juvenile nasal blood tumors
This trial tests whether sirolimus can shrink or control juvenile nasopharyngeal angiofibroma in children and teens, and checks its safety. It may help families who cannot rely only on surgery, especially for larger or hard-to-treat tumors.
MoscowAges 7–18 - NCT06071897RecruitingPhase 3
Chemo-immunotherapy for high-risk neuroblastoma
This trial tests a combination of chemotherapy and immunotherapy as a first treatment for children and young adults with high-risk neuroblastoma. The goal is to see if this approach can improve outcomes.
MoscowAges 1.5 years–18 years - NCT06198842RecruitingPhase 2
Low-dose treosulfan with PTCy for Nijmegen Breakage Syndrome transplant
This trial tests a low-dose chemotherapy regimen (treosulfan) combined with a drug called PTCy to prepare children with Nijmegen Breakage Syndrome for a stem cell transplant. The goal is to reduce side effects while helping the donor cells take hold safely.
MoscowAges 3 months–21 years - NCT06199427RecruitingPhase 2
Preventing graft-versus-host disease after stem cell transplant for immune disorders
This trial tests a combination of two drugs, ruxolitinib and PTCy, to prevent graft-versus-host disease (a common complication) in children receiving a stem cell transplant for inborn errors of immunity. The goal is to make the transplant safer and more effective.
MoscowAges birth–21 years - NCT07867522Recruiting
Preventing bile leaks after liver surgery in children
This study tests a way to prevent bile leaks after surgery to remove part of the liver in children. Bile is a digestive fluid made by the liver, and if it leaks after surgery it can cause problems. The approach involves a special technique during the operation to reduce the chance of this happening.
MoscowAges birth–18 years - NCT06296732Recruiting
Keyhole surgery for childhood neuroblastoma
This study looks at using keyhole (laparoscopic) surgery to remove neuroblastoma tumors in children. It groups tumors by risk factors to see which children can safely have this less invasive surgery.
MoscowAges 1 day–18 years
Hear when a new Pediatric Oncology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for pediatric oncology?
- Yes. Clin2 currently lists 66 recruiting pediatric oncology studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a pediatric oncology trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a pediatric oncology trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.